GHK-Cu Quick Start
GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a small copper-binding peptide that occurs naturally in human plasma. Levels are roughly 200 ng/mL around age 20 and fall to about 80 ng/mL by age 60. That decline is part of why GHK-Cu became a target for skin, hair, and wound-healing research.
Most clinical evidence is topical. Most community use is split between topical creams or serums and subcutaneous injection. This guide covers both routes side by side so the math, supplies, and evidence boundaries stay separate instead of blurring together.
Routes
Subcutaneous (SubQ) injection and topical formulations are the two main research-use routes.
Common range
Community discussions reference 1-2 mg per day SubQ or 1-3% topical formulations.
Measure
For injectable formats, vial size and reconstitution volume drive every draw calculation.
Supplies
Plan vials, BAC water, U-100 insulin syringes, and alcohol swabs by cycle length.
Status
Not FDA-approved. Injectable GHK-Cu was removed from FDA Category 2 on April 15, 2026.
Disclaimer
This page is an educational research reference and is not medical advice. Dosing context describes common community-derived research planning, not a personal protocol. Speak with a qualified clinician before any peptide use.
Use this page for GHK-Cu dosing, vial math, and handling. Want the wider science view? Read the GHK-Cu evidence guide. It covers copper peptide biology, research, safety, and comparisons.
GHK-Cu Dosing Protocol & Schedule
GHK-Cu is researched through two very different routes: subcutaneous injection of a reconstituted vial and topical application of a cream, serum, or microneedling-adjacent formulation. The route changes the dose, the cycle length, and the supplies you need. Choose the tab that matches the format you are researching.
GHK-Cu Protocol Formats
Choose the format you are researching to see route-specific dosing notes.
Subcutaneous injection of reconstituted GHK-Cu from a research-grade vial.
Common research-planning range
Community discussions and protocol-style references commonly describe 1-2 mg per day SubQ for a 4-8 week cycle. Lower starting points (around 1 mg/day) are typical for new research planning, and 2 mg/day is the high end most references cite. This is not a dosing recommendation.
Common Injectable Cycle Patterns
Approach
Conservative start
Daily dose
1.0 mg
Schedule
5 days on / 2 off
Cycle length
4 weeks
Approach
Standard
Daily dose
1.0-1.5 mg
Schedule
Daily
Cycle length
4-6 weeks
Approach
Higher end
Daily dose
1.5-2.0 mg
Schedule
Daily
Cycle length
6-8 weeks
| Approach | Daily dose | Schedule | Cycle length |
|---|---|---|---|
| Conservative start | 1.0 mg | 5 days on / 2 off | 4 weeks |
| Standard | 1.0-1.5 mg | Daily | 4-6 weeks |
| Higher end | 1.5-2.0 mg | Daily | 6-8 weeks |
Educational reference. No human RCT has confirmed an optimal injectable schedule for cosmetic or wound-healing endpoints.
Subcutaneous injections are typically rotated across the abdomen, outer thigh, and back of the upper arm. Many community references include 2-4 week off-periods between cycles to allow fresh evaluation, although the rationale is community-derived rather than trial-validated.
Cream, serum, or compounded topical formulations applied to skin or scalp.
Common topical formulation strengths
Cosmetic and compounded topical GHK-Cu products typically range from 1% to 3% by weight. Higher-end formulations sometimes cite 4-5%, but irritation reports rise with concentration. The 12-week study by Leyden and colleagues that anchors most topical evidence used a once- or twice-daily facial application.
Common Topical Application Patterns
Use case
Facial anti-aging (community use)
Concentration
1-2%
Frequency
Once or twice daily
Cycle length
8-12 weeks
Use case
Scalp / hair-research interest
Concentration
1-3%
Frequency
Daily
Cycle length
12+ weeks ongoing
Use case
Compounded post-procedure
Concentration
1-2%
Frequency
Per clinician guidance
Cycle length
Per clinician guidance
| Use case | Concentration | Frequency | Cycle length |
|---|---|---|---|
| Facial anti-aging (community use) | 1-2% | Once or twice daily | 8-12 weeks |
| Scalp / hair-research interest | 1-3% | Daily | 12+ weeks ongoing |
| Compounded post-procedure | 1-2% | Per clinician guidance | Per clinician guidance |
Topical concentrations are typically expressed as percent weight. A 1% serum is roughly 10 mg of GHK-Cu per gram of finished formulation.
Topical workflows are widely used because Copper Tripeptide-1 (the cosmetic name) is an established cosmetic ingredient. The clinical evidence base for topical use is stronger than for injection.
Evidence boundary
No published human randomized trial has evaluated long-term injectable GHK-Cu for skin, hair, or wound endpoints. The strongest human evidence is topical, including the Leyden 2002 photoaging trial and a 2023 IRB-approved 21-woman topical NEEL gel study reporting an average 28% increase in skin collagen density at 3 months.
GHK-Cu Reconstitution Guide
Reconstituting GHK-Cu is straightforward, but the route changes what you do with the reconstituted liquid. Injectable workflows draw from the vial directly. Topical workflows mix the reconstituted GHK-Cu into a base cream or serum.
Common Vial Sizes and Concentrations
Vial size
50 mg
BAC water
2.0 mL
Concentration
25.0 mg/mL
1 mg draw (U-100)
0.04 mL = 4 units
Vial size
50 mg
BAC water
2.5 mL
Concentration
20.0 mg/mL
1 mg draw (U-100)
0.05 mL = 5 units
Vial size
100 mg
BAC water
3.0 mL
Concentration
33.3 mg/mL
1 mg draw (U-100)
0.03 mL = 3 units
Vial size
100 mg
BAC water
5.0 mL
Concentration
20.0 mg/mL
1 mg draw (U-100)
0.05 mL = 5 units
| Vial size | BAC water | Concentration | 1 mg draw (U-100) |
|---|---|---|---|
| 50 mg | 2.0 mL | 25.0 mg/mL | 0.04 mL = 4 units |
| 50 mg | 2.5 mL | 20.0 mg/mL | 0.05 mL = 5 units |
| 100 mg | 3.0 mL | 33.3 mg/mL | 0.03 mL = 3 units |
| 100 mg | 5.0 mL | 20.0 mg/mL | 0.05 mL = 5 units |
Pick a reconstitution volume that produces a draw you can read cleanly on a U-100 syringe.
Standard Reconstitution Steps
- 01
Inspect the vial
Check label, supplier, and lot number. The lyophilized powder for GHK-Cu often appears off-white to pale blue depending on copper content and supplier process.
- 02
Prepare your supplies
Lay out one BAC water vial, one syringe for reconstitution, one syringe for the dose, and at least two alcohol swabs.
- 03
Swab both stoppers
Wipe the BAC water stopper and the GHK-Cu vial stopper with alcohol swabs and let them dry.
- 04
Draw bacteriostatic water
Draw the planned reconstitution volume from the BAC water vial.
- 05
Inject down the side of the vial
Aim the BAC water against the inner glass wall, not directly onto the powder. This protects the peptide from foaming and shear.
- 06
Swirl, do not shake
Roll the vial gently between your hands until the powder fully dissolves. The solution should look clear with a faint blue tint from the copper complex.
- 07
Store under refrigeration
Keep reconstituted GHK-Cu refrigerated and protected from light. Use within the supplier-stated beyond-use window.
Topical mixing note
For topical workflows, some compounded protocols mix reconstituted GHK-Cu into an unscented base cream or a hyaluronic-acid serum to hit a target percent. A 1% topical from a 100 mg vial reconstituted in 5 mL would mean roughly 0.5 mL (10 mg) blended into 1 g of finished base. Speak with a compounding pharmacist for exact formulation guidance.
If you want the math handled for you, use the peptide reconstitution calculator.
How GHK-Cu Works
GHK-Cu does two things at once. It carries copper into cells where copper-dependent enzymes need it, and the GHK fragment itself acts as a signaling peptide that influences gene expression in fibroblasts and other tissue cells. That dual role is part of why the research base touches so many systems: skin, hair follicles, wound beds, lung, gut, and bone in animal and cell models.
Mechanistically, GHK-Cu has been shown to stimulate collagen and elastin synthesis in dermal fibroblasts, increase decorin (a small proteoglycan that helps regulate collagen organization), and influence matrix metalloproteinases and their inhibitors. Broad gene-mapping work led by Pickart and colleagues reported modulation of thousands of genes, with roughly a third of human gene patterns shifting toward expression states associated with younger or healthier tissue.
The mechanism story is broad, but most of it is built on cell and animal models. The strongest human-level translation is in topical skin biology. Injectable systemic translation is still mostly indirect.
GHK-Cu Supplies Needed
Plan based on the injectable schedule above. Math is anchored to a 50 mg vial reconstituted with 2.0 mL bacteriostatic water (25 mg/mL), with one daily injection at 1 mg (0.04 mL = 4 units on a U-100 syringe). Topical workflows do not need vial or syringe math.
Recommended Supply
Use discount code PEPPAL at eligible peptide supplier checkouts.
GHK-Cu Supply (100mg)
GHK-Cu Supply
SiPhox Health At-Home Blood Test
Injection Supplies
Disclosure: supply links may earn PDP a commission at no cost to you.
Peptide Vials (Injectable)
Math anchored to 50 mg vials at 25 mg/mL after 2.0 mL reconstitution. One vial covers about 50 daily 1 mg doses; community planning typically rounds down for priming losses.
| Cycle length | Planning note |
|---|---|
4-6 weeks 1 vial | 4 weeks: 28 doses needed.; 6 weeks: 42 doses needed; one 50 mg vial is sufficient. |
8-12 weeks 2 vials | 8 weeks: 56 doses needed; second vial provides margin for losses.; 12 weeks: 84 doses needed; two 50 mg vials cover the cycle with headroom. |
4-6 weeks
1 vial
4 weeks: 28 doses needed.; 6 weeks: 42 doses needed; one 50 mg vial is sufficient.
8-12 weeks
2 vials
8 weeks: 56 doses needed; second vial provides margin for losses.; 12 weeks: 84 doses needed; two 50 mg vials cover the cycle with headroom.
Insulin Syringes (U-100)
Use 0.3 mL / 30-unit syringes for clean 4-unit (1 mg) draws. One syringe per injection.
| Cycle length | Planning note |
|---|---|
4 weeks 28 syringes | 1 syringe per daily injection. |
6 weeks 42 syringes | Most retail boxes are 100-count; one box covers 6-8 weeks. |
8 weeks 56 syringes | 1 box of 100 leaves headroom for losses. |
12 weeks 84 syringes | Still within a single 100-count box; round up for spoiled draws. |
4 weeks
28 syringes
1 syringe per daily injection.
6 weeks
42 syringes
Most retail boxes are 100-count; one box covers 6-8 weeks.
8 weeks
56 syringes
1 box of 100 leaves headroom for losses.
12 weeks
84 syringes
Still within a single 100-count box; round up for spoiled draws.
Bacteriostatic Water
Use 2.0 mL per 50 mg vial. Most BAC water sells in 10 mL bottles, which provides margin against waste.
| Cycle length | Planning note |
|---|---|
4-12 weeks 1 x 10 mL bottle | 4 weeks: 2 mL used; bottle covers 1 vial easily.; 6 weeks: 2 mL used.; 8 weeks: 4 mL used across 2 vials; one bottle is enough.; 12 weeks: 4 mL used; second bottle is optional safety margin. |
4-12 weeks
1 x 10 mL bottle
4 weeks: 2 mL used; bottle covers 1 vial easily.; 6 weeks: 2 mL used.; 8 weeks: 4 mL used across 2 vials; one bottle is enough.; 12 weeks: 4 mL used; second bottle is optional safety margin.
Round up for priming losses, dropped syringes, damaged swabs, and any protocol adjustments. Topical-only workflows do not need this supplies math.
Who GHK-Cu Is For and Who Should Avoid It
GHK-Cu is most often discussed by adults exploring skin-quality, hair-quality, or tissue-repair research, especially in the context of age-related collagen decline. The topical route has the broadest applicability and the longest cosmetic safety record.
Groups that should avoid or seek clinician guidance first
Pregnancy and breastfeeding: GHK-Cu has not been adequately studied in pregnancy or lactation. Avoid both injectable and topical use in these populations without clinician oversight.
Active cancer or untreated solid tumors: GHK-Cu modulates angiogenesis and gene expression. Effects in active malignancy are not well characterized, and most clinicians treat this as an exclusion until more data exists.
Wilson's disease or other copper-handling disorders: GHK-Cu delivers bioavailable copper. Anyone with a known copper metabolism disorder should not use GHK-Cu.
Allergy to copper: rare but possible. Test small topical patches before broader application.
Active skin infection at the application or injection site: defer use until the area is healed.
GHK-Cu Side Effects & Safety
GHK-Cu has a long topical safety record and a shorter, mostly anecdotal injectable record. Side-effect patterns are different by route.
Topical effects
Most reported topical effects are mild and local: redness, tingling, dryness, or transient irritation at the application site, typically more common with concentrations above 4%. Combining GHK-Cu with strong actives like high-strength retinoids or low-pH acids in the same routine can increase irritation. Most cosmetic sources recommend rotating actives instead of layering them.
Injectable effects
Reported injectable effects are mostly local: redness, mild swelling, transient warmth, or a slight blue-tinted bruise from the copper complex. Systemic effects are rare in user reports but are not well characterized in published trials.
Theoretical risks
Long-term or high-frequency use raises theoretical concerns about copper accumulation. GHK-Cu also stimulates both collagen synthesis and matrix metalloproteinases that break collagen down, so unbalanced or excessive use could in principle disrupt extracellular-matrix homeostasis. These risks are theoretical, not documented in human trials, but they are reasons community references include cycle off-periods.
Quality-control risk
Research-use peptide vials vary in purity, copper content, and reconstitution stability. A trustworthy COA from an independent lab is the best buyer-side check. Avoid vials with no batch-matched COA, no copper content data, or unclear supplier provenance.
GHK-Cu Timeline & What to Monitor
Topical clinical trials of GHK-Cu generally measured endpoints at 8-12 weeks. The Leyden 2002 facial-cream trial reported skin density, thickness, fine lines, and laxity changes at 12 weeks. The 2023 NEEL gel IRB study reported an average 28% increase in skin collagen density at 3 months. Injectable timelines are not well characterized in published trials, but community planning typically uses 4-8 week cycles for the same reason: change in skin or hair quality is slow to appear.
Common Endpoints by Route
Endpoint
Skin firmness or smoothness
Topical timeline
8-12 weeks
Injectable framing
Anecdotal; not trial-validated
Endpoint
Skin density (instrument-measured)
Topical timeline
12 weeks
Injectable framing
Anecdotal; not trial-validated
Endpoint
Wrinkle depth
Topical timeline
8-12 weeks
Injectable framing
Anecdotal
Endpoint
Hair shedding or thickness
Topical timeline
12+ weeks
Injectable framing
Anecdotal; mostly community-derived
Endpoint
Wound or scar texture
Topical timeline
Per-clinician
Injectable framing
Per-clinician
| Endpoint | Topical timeline | Injectable framing |
|---|---|---|
| Skin firmness or smoothness | 8-12 weeks | Anecdotal; not trial-validated |
| Skin density (instrument-measured) | 12 weeks | Anecdotal; not trial-validated |
| Wrinkle depth | 8-12 weeks | Anecdotal |
| Hair shedding or thickness | 12+ weeks | Anecdotal; mostly community-derived |
| Wound or scar texture | Per-clinician | Per-clinician |
Topical timelines are anchored to published trials. Injectable timelines are anchored to community planning, not RCTs.
Reasonable things to monitor over a cycle include before-and-after photos in consistent lighting, irritation or injection-site reactions, and any subjective changes in healing speed. Do not interpret photographic improvement as proof of mechanism in your own case.
GHK-Cu Clinical Evidence Context
The cleanest way to think about GHK-Cu evidence is by route. Topical evidence is stronger and includes IRB-approved human trials. Injectable evidence is mostly preclinical with strong mechanism data, plus community use.
Strongest human evidence (topical)
The Leyden 2002 photoaging trial in 71 women applied a GHK-Cu facial cream for 12 weeks and reported measurable improvements in skin density, thickness, fine lines, and laxity. A companion eye-cream study in 41 women compared GHK-Cu cream to placebo and vitamin K and reported greater periorbital improvement.
Recent human topical evidence
A 2023 IRB-approved 21-woman topical trial of NEEL gel (a stabilized GHK-Cu topical) reported an average 28% increase in skin collagen density at 3 months, with a top quartile reporting 51%.
Mechanism and gene expression
Pickart and colleagues used Broad Institute Connectivity Map data to show GHK-Cu modulates expression of more than 4,000 human genes, with shifts toward patterns associated with younger tissue. This is mechanism evidence, not outcome evidence.
Preclinical wound healing
Animal wound-healing studies in rats, mice, rabbits, and pigs reported faster wound contraction, increased collagen, and improved angiogenesis with GHK-Cu, including systemic effects when GHK-Cu was injected at one site and improved healing at distant sites.
Evidence gaps
No published human randomized trial has evaluated injectable GHK-Cu for cosmetic, hair, or wound endpoints. No long-term safety trial exists for injectable use. Topical strength does not automatically transfer to injectable strength.
GHK-Cu Storage & Handling
Storage Reference
State
Lyophilized (Powder Form)
Storage
-4F (-20C) long-term; refrigerated short-term
Notes
Use supplier label and stability data; protect from light.
State
Reconstituted (Liquid Form)
Storage
35.6-46.4F (2-8C)
Notes
Faint blue tint is normal from the copper complex; keep upright and protected from light.
State
Topical formulation
Storage
Per product label
Notes
Compounded topicals follow the compounder's beyond-use date.
| State | Storage | Notes |
|---|---|---|
| Lyophilized (Powder Form) | -4F (-20C) long-term; refrigerated short-term | Use supplier label and stability data; protect from light. |
| Reconstituted (Liquid Form) | 35.6-46.4F (2-8C) | Faint blue tint is normal from the copper complex; keep upright and protected from light. |
| Topical formulation | Per product label | Compounded topicals follow the compounder's beyond-use date. |
Discard reconstituted vials that look cloudy, develop particulates, or have changed color significantly beyond the expected blue tint.
GHK-Cu Protocol Mistakes & Troubleshooting
- 01
Reconstituted solution looks very dark or cloudy
A faint blue tint from copper is expected. Cloudiness or unusual particulates suggests poor reconstitution, contamination, or a quality issue. Discard and review supplier COA before reordering.
- 02
Topical product is causing irritation
Drop the application frequency, lower the concentration, and avoid layering with high-strength retinoids or acids in the same routine. Patch-test before reintroducing.
- 03
Injection site stays red or sore
Rotate sites across abdomen, thigh, and arm. Persistent reactions can indicate technique issues, vial contamination, or sensitivity. Stop and review with a clinician if symptoms persist.
- 04
Missed dose
For daily injectable workflows, skip the missed dose and continue on schedule. Do not double up.
- 05
Wrong BAC water volume
Recalculate concentration with the actual volume used. The math is the same: total mg divided by total mL equals mg/mL. Adjust the draw volume accordingly.
- 06
Storage mistake (left out at room temp)
Brief room-temperature exposure during dosing is expected. Prolonged exposure (multiple hours warm or in direct light) is a quality risk; some users discard rather than continue.
- 07
Persistent or unusual symptoms
Stop use and seek qualified medical care for any unusual systemic symptoms, allergic reactions, or persistent injection-site issues.
GHK-Cu Regulatory Status
GHK-Cu is not an FDA-approved drug. The cosmetic form (listed as Copper Tripeptide-1 on ingredient labels) is widely used in skincare and is regulated as a cosmetic, not a drug. The injectable form was placed on the FDA's Category 2 bulk drug substances list in 2023, restricting compounding pharmacies from preparing it under Section 503A.
April 2026 Category 2 Update
On April 15, 2026, the FDA confirmed removal of injectable GHK-Cu from Category 2 because the original nominations were withdrawn. The FDA announced it intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027 regarding potential inclusion of GHK-Cu on the 503A bulks list. Removal from Category 2 does not automatically grant Category 1 status; formal rulemaking is still required before compounding pharmacies can act on a reclassification.
WADA does not currently list GHK-Cu as a prohibited substance, although athletes are typically advised to confirm current prohibited-substance lists for their sport.
Research-use-only vials sold by gray-market peptide suppliers are not regulated as drugs and are not approved for human use. Buyers who choose this route typically rely on independent COAs and supplier reputation as the main quality-control levers.
GHK-Cu vs Topical Cosmetic Copper Peptides vs the GLOW Stack
GHK-Cu is often confused with the cosmetic ingredient "copper peptides" or with the GLOW stack, but the three are not interchangeable.
GHK-Cu vs Adjacent Categories
Format
Topical GHK-Cu (cosmetic)
What it is
Copper Tripeptide-1 in serums and creams
Evidence base
Strongest human evidence (Leyden 2002, NEEL 2023)
Typical use
Daily anti-aging skincare
Format
Injectable GHK-Cu (research-use)
What it is
Reconstituted vial, SubQ injection
Evidence base
Mostly preclinical; community use
Typical use
1-2 mg/day cycles
Format
GLOW stack (community blend)
What it is
GHK-Cu + BPC-157 + TB-500 in one vial
Evidence base
Compound-level only; no direct stack RCT
Typical use
Combined skin/recovery research
Format
Generic "copper peptides" (cosmetics)
What it is
Various copper-binding peptides, not all GHK-based
Evidence base
Mixed; depends on specific peptide
Typical use
Anti-aging skincare
| Format | What it is | Evidence base | Typical use |
|---|---|---|---|
| Topical GHK-Cu (cosmetic) | Copper Tripeptide-1 in serums and creams | Strongest human evidence (Leyden 2002, NEEL 2023) | Daily anti-aging skincare |
| Injectable GHK-Cu (research-use) | Reconstituted vial, SubQ injection | Mostly preclinical; community use | 1-2 mg/day cycles |
| GLOW stack (community blend) | GHK-Cu + BPC-157 + TB-500 in one vial | Compound-level only; no direct stack RCT | Combined skin/recovery research |
| Generic "copper peptides" (cosmetics) | Various copper-binding peptides, not all GHK-based | Mixed; depends on specific peptide | Anti-aging skincare |
Use this table to anchor the discussion you want to have. "Copper peptides" is a category, not a specific compound.
GHK-Cu Blood Tests & Monitoring
GHK-Cu is a copper peptide often discussed in skin, hair, wound, and tissue-repair research. Monitoring focuses on broad health markers, with copper-specific labs reserved for repeated or higher systemic exposure contexts.
Blood test markers to discuss with a clinician
Marker
CBC with differential
Why it matters
Screens anemia, white-cell patterns, and platelet changes that may matter when reviewing systemic health.
Timing
Baseline
Marker
Comprehensive metabolic panel (CMP)
Why it matters
Reviews liver and kidney markers, which matter for systemic exposure and copper handling context.
Timing
Baseline
Marker
Copper and ceruloplasmin
Why it matters
Adds copper-status context when repeated high-exposure copper peptide use is being discussed.
Timing
Optional
Marker
CRP
Why it matters
May help frame systemic inflammation when wound, skin, or connective-tissue symptoms are part of the protocol.
Timing
Optional
| Marker | Why it matters | Timing |
|---|---|---|
| CBC with differential | Screens anemia, white-cell patterns, and platelet changes that may matter when reviewing systemic health. | Baseline |
| Comprehensive metabolic panel (CMP) | Reviews liver and kidney markers, which matter for systemic exposure and copper handling context. | Baseline |
| Copper and ceruloplasmin | Adds copper-status context when repeated high-exposure copper peptide use is being discussed. | Optional |
| CRP | May help frame systemic inflammation when wound, skin, or connective-tissue symptoms are part of the protocol. | Optional |
Monitoring guidance is pathway-based, with copper and liver context added for repeated systemic exposure discussions.
At-home blood test option
Easy at home option to monitor core metrics during research cycles.
Partner link: PDP may earn a commission at no cost to you.
Simple timing framework
Baseline
Discuss baseline labs before repeated systemic use, especially with liver disease, copper metabolism concerns, anemia, or supplement stacking.
Follow-up
Repeat broad labs after 8-12 weeks if systemic use continues or symptoms change.
Longer term
For longer repeated exposure, copper-related labs may be reviewed periodically with a clinician.
How to interpret the labs
- Topical and systemic exposure contexts should not be treated the same.
- Copper labs are context-specific and are not needed for every casual skin-care discussion.
- Liver history, anemia, supplements, and copper exposure from other sources matter when interpreting results.
Do not wait for routine labs
Jaundice, severe abdominal pain, neurologic symptoms, or unexplained anemia should be reviewed medically. Allergic reactions or severe skin irritation should not be handled as routine monitoring.
FAQ
Q1: What is GHK-Cu?
GHK-Cu is a small peptide made of three amino acids (glycine, histidine, lysine) bound to a copper ion. It occurs naturally in human plasma and was first isolated in 1973 by Loren Pickart. Plasma levels decline with age, which is part of why it became a research target for skin, hair, and wound healing.
Q2: Is GHK-Cu FDA-approved?
No. GHK-Cu is not an FDA-approved drug. The topical cosmetic form (Copper Tripeptide-1) is regulated as a cosmetic ingredient. Injectable GHK-Cu was placed on the FDA's Category 2 list in 2023 and removed on April 15, 2026 because the nominations were withdrawn. The FDA announced PCAC review before the end of February 2027 for potential 503A bulks listing.
Q3: What is the typical GHK-Cu dosage?
Community-derived research planning typically uses 1-2 mg per day subcutaneous for injectable workflows and 1-3% topical formulations. This is an educational reference, not a personal dosing recommendation. No human randomized trial has confirmed an optimal injectable dose.
Q4: Is GHK-Cu better topical or injectable?
The strongest human clinical evidence is for topical use, including the Leyden 2002 photoaging trial and a 2023 NEEL gel topical study reporting an average 28% increase in skin collagen density at 3 months. Injectable evidence is mostly preclinical and community-derived. Topical is the more evidence-supported route, especially for skin endpoints.
Q5: How is GHK-Cu reconstituted?
A common pattern is a 50 mg vial reconstituted with 2.0 mL bacteriostatic water, producing 25 mg/mL. A 1 mg dose then equals 0.04 mL, or 4 units on a U-100 insulin syringe. Adjust BAC water volume to make the draw easy to read on your syringe.
Q6: What are the main side effects of GHK-Cu?
Topical effects are usually mild and local: redness, tingling, dryness, or transient irritation, more common above 4% concentration. Injectable effects are typically local: redness, mild swelling, or a slight blue-tinted bruise from the copper complex. Long-term safety in injectable use is not well characterized in published trials.
Q7: How long does it take to see results from GHK-Cu?
Topical trials measured skin endpoints at 8-12 weeks. The 2023 NEEL gel IRB study reported collagen-density change at 3 months. Injectable timelines are not trial-validated. Community planning typically uses 4-8 week cycles to allow time for skin or hair changes to become visible.
Q8: Can GHK-Cu be combined with BPC-157 and TB-500?
GHK-Cu, BPC-157, and TB-500 are commonly combined in the GLOW stack, an informal community blend. No direct stack RCT has evaluated the combination in humans. Compound-level evidence does not automatically validate the blend.
Q9: What is the GLOW stack?
The GLOW stack is a community-derived blend of GHK-Cu, BPC-157, and TB-500 used for combined skin and recovery research. It is not an FDA-approved product and has not been studied as a fixed-ratio combination in human trials.
Q10: Who should avoid GHK-Cu?
GHK-Cu should be avoided during pregnancy or breastfeeding, in active cancer or untreated solid tumors, in Wilson's disease or other copper-handling disorders, and in known copper allergy. Anyone with a serious medical condition should speak with a qualified clinician before considering use.
Q11: Is GHK-Cu medical advice?
No. This page is an educational research reference. Dosing context describes common community-derived research planning, not a personal protocol. Speak with a qualified clinician before any peptide use.
Sources & Research
- 1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences (2018)
- 2. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International (2015)
- 3. Pickart L, Vasquez-Soltero JM, Margolina A. The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health. Oxidative Medicine and Cellular Longevity (2012)
- 4. Pickart L, Margolina A. GHK-Cu may Prevent Oxidative Stress in Skin by Regulating Copper and Modifying Expression of Numerous Antioxidant Genes. Cosmetics (MDPI) (2015)
- 5. Leyden J, Stephens T, Finkey M, Appa Y, Barkovic S. Skin Care Benefits of Copper Peptide Containing Facial Cream (12-week trial in 71 women with photoaged skin). Proceedings of the American Academy of Dermatology Meeting (2002)
- 6. Yuvan Research Inc. Epigenetic mechanisms activated by GHK-Cu increase skin collagen density in clinical trial (IRB-approved 21-woman NEEL gel trial; mean 28% collagen density increase at 3 months). EurekAlert! / Yuvan Research (2023)
- 7. Wikipedia contributors. Copper peptide GHK-Cu. Wikipedia (2026)
- 8. Lin Z, Tang Q, Wu W, et al. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms. Frontiers in Pharmacology (2025)
- 9. U.S. Food and Drug Administration. 503A Bulks List — Status of Nominated Bulk Drug Substances (April 2026 update; GHK-Cu injectable removed from Category 2; PCAC consultation planned by end of February 2027). FDA.gov (2026)
- 10. SSRP Institute. FDA Announces Change in Status of 12 Peptides (BPC-157, TB-500, MOTs-C, Epitalon, KPV, Semax, GHK-Cu injectable, Melanotan II, LL-37, DSIP, PEG-MGF, DiHexa). SSRP Institute News (2026)
- 11. Badenhorst T, Svirskis D, Wu Z. Pharmaceutical Strategies for the Topical Dermal Delivery of Peptides/Proteins for Cosmetic and Therapeutic Applications. Journal of Pharmaceutics (2016)
- 12. Pickart L. The human tri-peptide GHK and tissue remodeling (review of preclinical wound-healing data across rats, mice, rabbits, and pigs). Journal of Biomaterials Science, Polymer Edition (2008)
Related Dosing Protocols
Written by Garret Grant
Founder & Lead Researcher · B.S. Civil Engineering, UCLA
Last updated: May 2026
Human-researched and AI-assisted with full editorial review. I verify sources, protocol interpretation, and final judgments personally. See methodology.
Share this page